Solution phase routes for WNT hexapeptides
US-11970551-B2 · Apr 30, 2024 · US
Ethanol dependence of alpha1 antitrypsin C-terminal Lys truncation by basic carboxypeptidases
US9512172B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9512172-B2 |
| Application number | US-201414288342-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 27, 2014 |
| Priority date | May 19, 2006 |
| Publication date | Dec 6, 2016 |
| Grant date | Dec 6, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of making an alpha-1-proteinase inhibitor composition comprising des-lys alpha-1 proteinase inhibitor from human plasma, the method comprising the step of: treating a plasma precipitate comprising alpha-1-proteinase inhibitor with ethanol at a concentration of at least 5% and less than 15%, wherein the plasma precipitate is selected from the group consisting of a Cohn fraction IV-1 precipitate and a Cohn fraction IV-1+IV-4 precipitate. 2. The method of claim 1 , comprising treating the Cohn fraction IV-1 or IV-1+IV-4 precipitate with ethanol at a final concentration of less than 15% and more than 10%. 3. The method of claim 1 , comprising treating the Cohn fraction IV-1 or IV-1+IV-4 precipitate with ethanol at a final concentration of at least 5% and less than 10%. 4. The method of claim 1 , wherein the amount of des-lys alpha-1-proteinase inhibitor in the composition treated with ethanol is less than 65% and more than 2% of total alpha-1-proteinase inhibitor in the composition. 5. The method of claim 2 , wherein the amount of des-lys alpha-1-proteinase inhibitor in the composition treated with ethanol is less than 65% and more than 2% of total alpha-1-proteinase inhibitor in the composition. 6. The method of claim 3 , wherein the amount of des-lys alpha-1-proteinase inhibitor in the composition treated with ethanol is less than 65% and more than 2% of total alpha-1-proteinase inhibitor in the composition. 7. The method of claim 1 , wherein the amount of des-lys alpha-1-proteinase inhibitor in the composition treated with ethanol is less than 65% and more than 6% of total alpha-1-proteinase inhibitor in the composition. 8. The method of claim 2 , wherein the amount of des-lys alpha-1-proteinase inhibitor in the composition treated with ethanol is less than 65% and more than 6% of total alpha-1-proteinase inhibitor in the composition. 9. The method of claim 3 , wherein the amount of des-lys alpha-1-proteinase inhibitor in the composition treated with ethanol is less than 65% and more than 6% of total alpha-1-proteinase inhibitor in the composition. 10. The method of claim 3 , wherein the amount of des-lys alpha-1-proteinase inhibitor in the composition treated with ethanol is less than 6% and more than 2% of total alpha-1-proteinase inhibitor in the composition. 11. The method of claim 1 , wherein the Cohn fraction IV-1 or IV-1+IV-4 precipitate is treated at a pH of at least 5.2 and less than pH 5.9. 12. The method of claim 2 , wherein the Cohn fraction IV-1 or IV-1+IV-4 precipitate is treated at a pH of at least 5.2 and less than pH 5.9. 13. The method of claim 3 , wherein the Cohn fraction IV-1 or IV-1+IV-4 precipitate is treated at a pH of at least 5.2 and less than pH 5.9. 14. The method of claim 1 , wherein the plasma precipitate is a Cohn fraction IV-1 precipitate. 15. The method of claim 2 , wherein the plasma precipitate is a Cohn fraction IV-1 precipitate. 16. The method of claim 3 , wherein the plasma precipitate is a Cohn fraction IV-1 precipitate. 17. The method of claim 1 , wherein the plasma precipitate is a Cohn fraction IV-1+IV-4 precipitate. 18. The method of claim 2 , wherein the plasma precipitate is a Cohn fraction IV-1+IV-4 precipitate. 19. The method of claim 3 , wherein the plasma precipitate is a Cohn fraction IV-1+IV-4 precipitate.
Assignees
Inventors
Classifications
- C07K1/30Primary
by precipitation · CPC title
alpha-Glycoproteins · CPC title
from animals; from humans {(A61K38/553, A61K38/556 take precedence)} · CPC title
- C07K14/8125Primary
Alpha-1-antitrypsin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9512172B2 cover?
- Methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same are provided.
- Who is the assignee on this patent?
- Baxalta Inc, Baxalta GmbH
- What technology area does this patent fall under?
- Primary CPC classification C07K1/30. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).